{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/stroke-tia/management/secondary-prevention-following-stroke-tia/","result":{"pageContext":{"chapter":{"id":"91d820f4-4249-556c-99e2-4ac86d3ebd2a","slug":"secondary-prevention-following-stroke-tia","fullItemName":"Scenario: Secondary prevention following stroke and TIA","depth":2,"htmlHeader":"<!-- begin field 0db9cf06-fbbc-4e43-bdcc-926af4a1c1cd --><h2>Scenario: Secondary prevention following stroke and TIA</h2><!-- end field 0db9cf06-fbbc-4e43-bdcc-926af4a1c1cd -->","summary":"Covers secondary prevention following stroke and TIA. This section includes information on driving and employment.","htmlStringContent":"<!-- begin item ad75c574-60be-4cfd-8a14-bd1deca56da6 --><!-- begin field 84cf900b-b0ad-44af-9a5d-acbc015b9d31 --><p>From age 16 years onwards.</p><!-- end field 84cf900b-b0ad-44af-9a5d-acbc015b9d31 --><!-- end item ad75c574-60be-4cfd-8a14-bd1deca56da6 -->","topic":{"id":"f543bb01-4edc-57a6-ba31-aaa6b6b6e6e8","topicId":"63954e32-591d-4f33-bcbb-3fdecfc69796","topicName":"Stroke and TIA","slug":"stroke-tia","lastRevised":"Last revised in August 2020","chapters":[{"id":"3690cd7d-0a6b-548a-a527-b276c3924bab","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"aef0c419-4ee2-52b6-b781-c8afa9a11104","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"f8baebfc-07d7-5c4a-8d95-4d2bf1f42c38","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"3fa3210c-0be8-5167-adb3-6c05aaef00bc","slug":"changes","fullItemName":"Changes"},{"id":"e606f403-4b76-5e30-a38d-6aa4b6e3b4b1","slug":"update","fullItemName":"Update"}]},{"id":"fe337d01-2447-58d3-93e8-a6b09a4920d4","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"08277b76-a6c4-566a-a594-131c32067735","slug":"goals","fullItemName":"Goals"},{"id":"acf4fa85-325c-5018-8bc2-9d877522bf6f","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"18bc44dc-3e6b-58ae-9d3c-abca76b13c16","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"4eb59f42-29b3-56e1-993f-1ce8ab7b2969","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"08107877-662b-59e6-a30a-b21e19250f23","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"ff061807-ab05-5af8-8dd4-01db71526d0f","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"a0b319c1-8df3-5206-93ce-302f6b981e82","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"a0bcd779-defb-50a7-86f6-ab4b2c701ac7","slug":"definition","fullItemName":"Definition"},{"id":"c40d717d-0b67-5cb2-b86c-c67045400115","slug":"causes-risk-factors","fullItemName":"Causes and risk factors"},{"id":"d1569ff2-5da1-51a0-9720-75ad88c0ad86","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"ee8fc150-6899-5c75-a0d0-6241055dfd09","slug":"prevalence","fullItemName":"Prevalence"},{"id":"d5730239-5d67-598b-b9d1-f339079de3eb","slug":"complications","fullItemName":"Complications"},{"id":"9b730ca3-d3ee-552b-8145-f6eadf244a63","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"caea5ae7-0be8-5c7c-8bef-7162c7171e9d","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"67902a93-a36b-58c6-a67a-3eb89654460c","slug":"clinical-features","fullItemName":"Clinical features"},{"id":"2bc808d1-f905-575d-90b2-8481eb492905","slug":"assessment","fullItemName":"Assessment"},{"id":"6562a8bf-1396-58ba-b1b9-a1914e4adebe","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"2d634696-3361-5fd3-b676-609f3c31c2f1","fullItemName":"Management","slug":"management","subChapters":[{"id":"1baf2362-0da4-599f-8f9a-12d0124253a0","slug":"suspected-acute-stroke","fullItemName":"Scenario: Suspected acute stroke"},{"id":"15af1682-8287-57f9-90f1-954c1f71792e","slug":"suspected-transient-ischaemic-attack","fullItemName":"Scenario: Suspected transient ischaemic attack"},{"id":"91d820f4-4249-556c-99e2-4ac86d3ebd2a","slug":"secondary-prevention-following-stroke-tia","fullItemName":"Scenario: Secondary prevention following stroke and TIA"},{"id":"84ca3884-d693-5209-b048-6ff53b4ae2be","slug":"management-of-long-term-complications-of-stroke","fullItemName":"Scenario: Management of long term complications of stroke"}]},{"id":"30a83b67-7804-5b41-a647-98d32dce018a","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"ebfe1dbe-0d9c-5a26-82b4-4d0a308a19ac","slug":"antiplatelet-treatment","fullItemName":"Antiplatelet treatment"}]},{"id":"279444c7-61df-5f92-b512-c703ae6cb9fb","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"8ef8b6ac-1d47-5038-b4d7-4d77faf1a823","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"72590587-c86f-5da1-b397-b7e6cc757702","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"7ba85ca6-985e-5af5-b223-0c27f7066797","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"b322154e-a2d3-59d1-a7b2-d70b4e7812da","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"18f7eefe-52bd-5ad8-a39c-b96d270599ff","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"8fed8545-5194-53a4-b547-2d6a402857f5","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"216e65b7-f638-5b35-ad86-30270fbea649","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"2d634696-3361-5fd3-b676-609f3c31c2f1","slug":"management","fullItemName":"Management"},"subChapters":[{"id":"0b58143c-259f-5e4b-b3ef-165bfa9b08c6","slug":"secondary-prevention-following-stroke-tia","fullItemName":"Secondary prevention following stroke and TIA","depth":3,"htmlHeader":"<!-- begin field 32e1ab5f-6e28-492c-81aa-1523e7a30b3a --><h3>How should I follow up a person who has had a stroke or TIA?</h3><!-- end field 32e1ab5f-6e28-492c-81aa-1523e7a30b3a -->","summary":null,"htmlStringContent":"<!-- begin item af2d7f57-a2c5-4b28-a148-7494fd458c1e --><!-- begin field 6bb80009-e7d5-42fe-a54d-9e933288ee52 --><ul><li><strong>Secondary</strong> <strong>preventative measures are initiated at diagnosis in secondary care.</strong><ul><li>Arrange follow up in primary care on discharge, at 6 months and then at least annually to review health, social care needs (such as access to benefits, community participation, housing and return to work), ongoing risk factors, and secondary prevention.</li><li>Arrange review of carers of people with stroke at 6 months and then annually to assess their health and social care needs.</li></ul></li><li><strong>Offer information on stroke, transient ischaemic attack (TIA) and vascular risk factors to people with stroke or TIA and their family/carers:</strong><ul><li><a href=\"http://www.stroke.org.uk/shop/information-leaflets\" target=\"_blank\" data-hyperlink-id=\"5f73335a-051f-4a78-a83e-a8f70158b5b0\">Patient information</a> is available from the <a href=\"http://www.stroke.org.uk/\" target=\"_blank\" data-hyperlink-id=\"6bfe4dbf-e8b5-465f-8731-a8f70158b5db\">Stroke Association</a>.</li><li>Provide advice about <a class=\"topic-reference internal-reference\" href=\"/topics/stroke-tia/management/secondary-prevention-following-stroke-tia/#driving-work-advice\">driving</a> if appropriate.</li><li>Provide advice about <a class=\"topic-reference internal-reference\" href=\"/topics/stroke-tia/management/secondary-prevention-following-stroke-tia/#driving-work-advice\">returning to work</a> if appropriate.</li></ul></li><li><strong>Advise the person on lifestyle measures</strong>:<ul><li><strong>Encourage physical activity every day:</strong><ul><li>Advise the person to minimize time spent sitting for long periods (unless there are contraindications).</li><li>Individualized exercise programs (which may include muscle strengthening, balance and co-ordination activities) for people with stroke should be prescribed, delivered and monitored by the rehabilitation team.</li></ul></li><li><strong>Advise smokers to stop and non-smokers to avoid passive smoking:</strong><ul><li>Options to help with smoking cessation include referral to an NHS Stop Smoking Service, drug treatment, and written patient information. For further information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/smoking-cessation/\">Smoking cessation</a>.</li></ul></li><li><strong>Advise the person that diet optimization can help reduce cardiovascular disease (CVD) risk — they should aim to:</strong><ul><li>Eat at least five portions of fruit and vegetables (from a variety of sources) per day and two portions of oily fish per week.</li><li>Reduce intake of saturated fats.</li><li>Keep salt intake low — salt should not be added at the table, and processed foods should be kept to a minimum.</li><li>For further information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/cvd-risk-assessment-management/\">CVD risk assessment and management</a>.</li></ul></li><li><strong>Advise people who drink alcohol to keep consumption within the recommended limits:</strong><ul><li>Alcohol intake should be limited to 14 units a week, spread over at least three days.</li><li>For further information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/cvd-risk-assessment-management/\">CVD risk assessment and management</a>.</li></ul></li><li><strong>Advise against routine dietary supplementation with:</strong><ul><li>B vitamins or folate; vitamins A, C, or E; selenium; and calcium with or without vitamin D unless required for other medical conditions.</li></ul></li></ul></li><li><strong>Review medications used in secondary prevention:</strong><ul><li><strong>Antiplatelet therapy</strong> is initiated by secondary care on diagnosis of ischaemic stroke or TIA without paroxysmal or permanent atrial fibrillation for long-term vascular prevention:<ul><li>The standard treatment is clopidogrel 75mg daily (licenced for use in ischaemic stroke, off-label use in TIA).</li><li>Modified-release dipyridamole 200 mg twice daily may be used if both clopidogrel and aspirin are contraindicated or cannot be tolerated.</li><li>Aspirin 75mg daily may be used if both clopidogrel and modified-release dipyridamole are contraindicated or cannot be tolerated.</li><li>Aspirin 75 mg daily with modified-release dipyridamole 200 mg twice daily may be used if clopidogrel cannot be tolerated.</li><li>Dual therapy with aspirin and clopidogrel may be initiated in secondary care for the first three months following ischaemic stroke or TIA due to severe symptomatic intracranial stenosis or for another condition such as acute coronary syndrome.</li><li>If benefit outweighs risk, people with haemorrhagic transformation following ischaemic stroke may be started on long-term antiplatelet therapy by secondary care.</li></ul></li><li><strong>Lipid modification drug treatment</strong><ul><li>Unless contraindicated, treatment with a high intensity statin (such as atorvastatin 20–80mg daily) will be offered at diagnosis of ischaemic stroke or TIA by secondary care.  The aim of statin therapy is to reduce non-HDL cholesterol by more than 40%.</li><li>If this reduction is not achieved within 3 months, consider adherence, diet, lifestyle, and increasing dose (if appropriate) – discuss with a stroke specialist if unsure.</li><li>Fibrates, bile acid sequestrants, nicotinic acid and omega-3 fatty acid compounds should <em>not </em>be prescribed to people with ischaemic stroke or TIA for secondary vascular prevention. Ezetimibe should be used only in people who also have familial hypercholesterolaemia.</li><li>Statin treatment should be avoided in people with primary intracerebral haemorrhage unless advised for other indications.</li><li>For further information on lipid modification therapy, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/cvd-risk-assessment-management/\">CVD risk assessment and management</a>. If in doubt about management of lipids in stroke and TIA discuss with a stroke specialist.</li></ul></li><li><strong>Anti-hypertensive drugs</strong><ul><li>Treatment for hypertension following stroke or TIA should be initiated by secondary care following diagnosis and may include a thiazide-like diuretic, long-acting calcium channel blocker or angiotensin-converting enzyme inhibitor.</li><li>Monitor blood pressure-lowering treatment frequently and adjust treatment as tolerated to achieve a target systolic blood pressure below 130 mmHg (or 140–150 mmHg in people with severe bilateral carotid artery stenosis).</li><li>Blood pressure reduction in people with stroke should be gradual and sustained — caution is required especially in people with carotid or vertebrobasilar occlusive disease.</li><li>If blood pressure remains above target despite treatment, check adherence and discuss with a stroke specialist.</li><li>For detailed information on management of hypertension, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/hypertension-not-diabetic/\">Hypertension - not diabetic</a>.</li></ul></li><li><strong>Anticoagulant drugs </strong>will be initiated in secondary care for people with ischaemic stroke or TIA and paroxysmal, persistent or permanent atrial fibrillation or atrial flutter once intracranial bleeding and other contraindications (such as uncontrolled hypertension) are excluded.<ul><li>Treatment in people with TIA will start immediately on diagnosis once imaging has excluded haemorrhage.</li><li>Treatment is deferred for variable periods in people with non-disabling ischaemic stroke depending on specific circumstances but starts within 14 days of onset.</li><li>Treatment is deferred until at least 14 days from onset in people with disabling ischaemic stroke. In the interim aspirin 300 mg daily will be used.</li><li>Anticoagulation for people with TIA or stroke should be with adjusted-dose warfarin (target INR 2.5, range 2.0 to 3.0) or a direct thrombin or factor Xa inhibitor (for people with non-valvular AF).</li><li>Anticoagulation should not be used in people with stroke or TIA in sinus rhythm unless other indications (such as a cardiac source of embolism, cerebral venous thrombosis or arterial dissection) are present.</li><li>Do not prescribe antiplatelet therapy as an alternative to anticoagulation in people with cardioembolic stroke and a contraindication (such as undiagnosed bleeding). Identify modifiable risk factors (using a tool such as HAS-BLED) and attempt to reduce bleeding risk. Alternative treatments such as a left atrial appendage occlusion device may be appropriate. For more information on the HAS-BLED tool, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/atrial-fibrillation/\">Atrial fibrillation</a>.</li><li>Antithrombotic treatment in people with recurrent TIA or stroke should be the same as for those with a single event — more intensive antithrombotic therapy should only be as part of a clinical trial or in exceptional clinical circumstances.</li><li>For further information on anticoagulation and antiplatelet therapy see the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/atrial-fibrillation/\">Atrial fibrillation</a> and <a class=\"topic-reference external-reference\" href=\"/topics/antiplatelet-treatment/\">Antiplatelet treatment</a>. If in doubt about antithrombotic therapy seek specialist advice.</li></ul></li></ul></li><li><strong>Optimize management of other comorbidities and <a class=\"topic-reference internal-reference\" href=\"/topics/stroke-tia/background-information/causes-risk-factors/\">risk factors</a> such as:</strong><ul><li><strong>Diabetes mellitus</strong><ul><li>For further information on the management of diabetes mellitus see the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/diabetes-type-1/\">Diabetes - type 1</a> and <a class=\"topic-reference external-reference\" href=\"/topics/diabetes-type-2/\">Diabetes - type 2</a>.</li></ul></li><li><strong>Obstructive sleep apnoea </strong><ul><li>People with stroke or TIA should be screened for obstructive sleep apnoea with a valid clinical screening tool.  Refer anyone suspected of having sleep apnoea for a respiratory/sleep medicine assessment. For further information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/obstructive-sleep-apnoea-syndrome/\">Obstructive sleep apnoea syndrome</a>.</li></ul></li><li><strong>Heart failure</strong><ul><li>For further information on the management of heart failure see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/heart-failure-chronic/\">Heart failure - chronic</a>.</li></ul></li><li><strong>Contraception</strong><ul><li>Do <em>not</em> offer pre-menopausal women with stroke or TIA the combined oral contraceptive pill. Consider progestogen-only and non-hormonal contraceptive methods instead. For further information, see the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/contraception-assessment/\">Contraception - assessment</a>, <a class=\"topic-reference external-reference\" href=\"/topics/contraception-barrier-methods-spermicides/\">Contraception - barrier methods and spermicides</a> and <a class=\"topic-reference external-reference\" href=\"/topics/contraception-progestogen-only-methods/\">Contraception - progestogen-only methods</a>.</li></ul></li><li><strong>Menopause</strong><ul><li>Advise post-menopausal women with ischaemic stroke or TIA who wish to start or continue hormone replacement therapy on the risks and benefits of treatment. For further information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/menopause/\">Menopause</a>.</li><li>Do not offer post-menopausal women with ischaemic stroke or TIA hormone replacement therapy for secondary vascular prevention.</li></ul></li><li><strong>Influenza</strong><ul><li>Arrange annual pre-winter influenza immunizations.</li></ul></li></ul></li></ul><!-- end field 6bb80009-e7d5-42fe-a54d-9e933288ee52 --><!-- end item af2d7f57-a2c5-4b28-a148-7494fd458c1e -->","subChapters":[{"id":"4aebeb55-9f1f-5279-aed6-1ab0acbec37f","slug":"driving-work-advice","fullItemName":"Driving and work advice","depth":4,"htmlHeader":"<!-- begin field 9a2560cc-62a2-42b5-88da-a73100972cb3 --><h4>What advice should I give on driving and work?</h4><!-- end field 9a2560cc-62a2-42b5-88da-a73100972cb3 -->","summary":null,"htmlStringContent":"<!-- begin item f1615f6e-3106-495a-a39c-a73100972c6e --><!-- begin field e4915f37-26ed-4dd5-b7d1-a73100972cb3 --><ul><li><strong>Driving</strong><ul><li>Discuss the exclusion period and the person’s responsibility to notify the Driver and Vehicle Licencing Agency (DVLA) after stroke or TIA — up to date guidance on assessing fitness to drive is available online from the DVLA  '<a href=\"https://www.gov.uk/guidance/assessing-fitness-to-drive-a-guide-for-medical-professionals\" target=\"_blank\" data-hyperlink-id=\"18ad121b-fab4-4ecc-9024-a8f7015ad109\">Assessing fitness to drive: a guide for medical professionals guide for medical professionals</a>'  [<a class=\"bibliography-reference internal-reference\" href=\"/topics/stroke-tia/references/\">RCP, 2016</a>].</li><li>Refer people with persisting cognitive, language or motor disability after stroke who wish to return to driving for on-road screening and evaluation [<a class=\"bibliography-reference internal-reference\" href=\"/topics/stroke-tia/references/\">RCP, 2016</a>].</li><li>Inform people who wish to drive after stroke about eligibility for disabled concessions (for example the Blue Badge scheme) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/stroke-tia/references/\">RCP, 2016</a>].</li></ul></li><li><strong>Work</strong> — if the person wishes to return to work after stroke [<a class=\"bibliography-reference internal-reference\" href=\"/topics/stroke-tia/references/\">NICE, 2010a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/stroke-tia/references/\">RCP, 2016</a>]:<ul><li>Discuss the need for assessment for return to work with the rehabilitation team.</li><li>The person can be referred through the job centre to a specialist in employment for people with disability or to the specialist vocational rehabilitation team if extra support or advice is needed.</li></ul></li></ul><!-- end field e4915f37-26ed-4dd5-b7d1-a73100972cb3 --><!-- end item f1615f6e-3106-495a-a39c-a73100972c6e -->","subChapters":[]},{"id":"cd8176ee-464e-5539-8866-54f97ae1d0d2","slug":"basis-for-recommendation-218","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field b98d76eb-8d53-4b1f-892c-8405c44bfdbf --><h4>Basis for recommendation</h4><!-- end field b98d76eb-8d53-4b1f-892c-8405c44bfdbf -->","summary":null,"htmlStringContent":"<!-- begin item 218c62c7-0f6e-4323-8ef5-594f0fe24e57 --><!-- begin field 6dc9f4a3-b600-4804-8221-c307432752a1 --><p>The recommendations on secondary prevention following stroke or transient ischaemic attack (TIA) are based on the clinical guidelines <em>Stroke rehabilitation in adults</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/stroke-tia/references/\">National Clinical Guideline Centre, 2013</a>], <em>Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/stroke-tia/references/\">Jauch, 2013</a>], <em>Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/stroke-tia/references/\">Kernan, 2014</a>], <em>Stroke and transient ischemic attack: acute and long term management</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/stroke-tia/references/\">British Columbia Medical Association, 2015</a>], National clinical guideline for stroke: prepared by the Intercollegiate Stroke Working Party [<a class=\"bibliography-reference internal-reference\" href=\"/topics/stroke-tia/references/\">RCP, 2016</a>], and <em>Guidelines for Adult Stroke Rehabilitation and Recovery: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/stroke-tia/references/\">Winstein, 2016</a>] and expert opinion in review articles [<a class=\"bibliography-reference internal-reference\" href=\"/topics/stroke-tia/references/\">Hankey, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/stroke-tia/references/\">Eskes, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/stroke-tia/references/\">Wein, 2015</a>].</p><h5>Offer information on stroke, TIA and vascular risk factors</h5><ul><li>Patient education and follow up information should be provided initially by secondary care and offered again and reinforced in primary care [<a class=\"bibliography-reference internal-reference\" href=\"/topics/stroke-tia/references/\">British Columbia Medical Association, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/stroke-tia/references/\">RCP, 2016</a>].</li></ul><p><strong>Diet and lifestyle measures</strong> — diet and lifestyle factors are known to contribute to risk of cardiovascular events including first and recurrent stroke. However, there is a lack of high quality evidence for specific lifestyle interventions in the secondary prevention of stroke and TIA. Available evidence on lifestyle interventions relates mainly to primary prevention of vascular events [<a class=\"bibliography-reference internal-reference\" href=\"/topics/stroke-tia/references/\">RCP, 2016</a>].</p><ul><li><strong>Physical activity</strong><ul><li>Physical inactivity after stroke can lead to deconditioning, increased risk of falls and may contribute to increased risk of subsequent cardiovascular events. Exercise training can improve quality of life, functional capacity and performance of activities of daily living [<a class=\"bibliography-reference internal-reference\" href=\"/topics/stroke-tia/references/\">Billinger, 2014</a>].</li><li>Prescription of physical activity and exercise for people with stroke survivors should be tailored to the individual and emphasize low- to moderate-intensity aerobic activity, muscle-strengthening activity, and reduction of sedentary behaviour [<a class=\"bibliography-reference internal-reference\" href=\"/topics/stroke-tia/references/\">Billinger, 2014</a>].</li></ul></li><li><strong>Diet</strong><ul><li>The American Heart Association/American Stroke Association recommend advising people with stroke or TIA to follow a Mediterranean-type diet (emphasizing vegetables, fruits, and whole grains and including low-fat dairy products, poultry, fish, legumes, olive oil, and nuts and limiting intake of sweets and red meats) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/stroke-tia/references/\">Kernan, 2014</a>].</li><li>Reduction in blood pressure has been associated with several lifestyle modifications including salt restriction, consumption of a diet rich in fruits, vegetables, and low-fat dairy products, regular aerobic physical activity and limited alcohol consumption [<a class=\"bibliography-reference internal-reference\" href=\"/topics/stroke-tia/references/\">Kernan, 2014</a>].</li></ul></li><li><strong>Micronutrient supplementation: </strong><ul><li>The American Heart Association/American Stroke Association advises against routine supplementation with single or combination vitamins [<a class=\"bibliography-reference internal-reference\" href=\"/topics/stroke-tia/references/\">Kernan, 2014</a>].</li><li>A Cochrane review looking at the use of B-vitamin supplementation in prevention of cardiac events found no benefit for supplementation with vitamins B6, B9 or B12 [<a class=\"bibliography-reference internal-reference\" href=\"/topics/stroke-tia/references/\">Mart&iacute;-Carvajal, 2015</a>]. </li><li>Two meta-analyses [<a class=\"bibliography-reference internal-reference\" href=\"/topics/stroke-tia/references/\">Alkhenizan, 2004</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/stroke-tia/references/\">Bin, 2011</a>] and one systematic review [<a class=\"bibliography-reference internal-reference\" href=\"/topics/stroke-tia/references/\">Eidelman, 2004</a>] found no benefit on stroke recurrence and mortality with vitamin E supplementation.</li><li>Supplementation of diet with calcium and/or vitamin D has not been shown to reduce cardiovascular risk [<a class=\"bibliography-reference internal-reference\" href=\"/topics/stroke-tia/references/\">Elamin, 2011</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/stroke-tia/references/\">Bolland, 2014</a>]. One systematic review found a modest increase in risk [<a class=\"bibliography-reference internal-reference\" href=\"/topics/stroke-tia/references/\">Bolland et al, 2010</a>].</li><li>It is not known how other supplements such as plant stanols/sterols, antioxidants (including vitamins A and C) and selenium affect stroke [<a class=\"bibliography-reference internal-reference\" href=\"/topics/stroke-tia/references/\">Hookway, 2014</a>].</li></ul></li></ul><h5>Review medications used in secondary prevention</h5><ul><li><strong>Antiplatelet therapy in ischaemic stroke and TIA </strong>— recommendations on antiplatelet therapy are based on the UK national clinical guideline on stroke [<a class=\"bibliography-reference internal-reference\" href=\"/topics/stroke-tia/references/\">RCP, 2016</a>].<ul><li>Antiplatelet therapy reduces the risk of recurrent vascular events including stroke [<a class=\"bibliography-reference internal-reference\" href=\"/topics/stroke-tia/references/\">RCP, 2016</a>].<ul><li>The Antithrombotic Trialists’ Collaboration [<a class=\"bibliography-reference internal-reference\" href=\"/topics/stroke-tia/references/\">Antithrombotic Trialists' Collaboration, 2002</a>] found a 22% reduction in the odds of a vascular event (including myocardial infarction, stroke or vascular death) in people with stroke or TIA who were treated with antiplatelet medication.</li></ul></li><li>NICE technology appraisal TA210 recommends clopidogrel as the most cost-effective antiplatelet therapy for secondary prevention following ischaemic stroke [<a class=\"bibliography-reference internal-reference\" href=\"/topics/stroke-tia/references/\">NICE, 2010b</a>]. <ul><li>The Clopidogrel Versus Aspirin in Patients at Risk of Ischemic Events comparative trial (CAPRIE) randomized over 19 000 patients with stroke, MI, or peripheral vascular disease to aspirin 325 mg/day or clopidogrel 75 mg/day. The annual rate of ischemic stroke, MI, or vascular death was 5.32% among patients assigned to clopidogrel compared with 5.83% among patients assigned to aspirin (RRR, 8.7%; 95% CI, 0.3%–16.5%; P=0.043 [<a class=\"bibliography-reference internal-reference\" href=\"/topics/stroke-tia/references/\">CAPRIE Steering Committee, 1996</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/stroke-tia/references/\">Kernan, 2014</a>].</li></ul></li><li>NICE recommends aspirin plus modified-release dipyridamole for the management of TIA as clopidogrel is not licensed for this indication [<a class=\"bibliography-reference internal-reference\" href=\"/topics/stroke-tia/references/\">NICE, 2010b</a>].<ul><li>The Intercollegiate Working Party recognise the recommendation from NICE but consider that a unified approach to the treatment of TIA and ischaemic stroke is more appropriate as the benefits of recommending clopidogrel first-line outweigh any disadvantages [<a class=\"bibliography-reference internal-reference\" href=\"/topics/stroke-tia/references/\">RCP, 2016</a>].</li></ul></li><li>Combination antiplatelet therapy may be more effective than monotherapy but has a greater risk of bleeding [<a class=\"bibliography-reference internal-reference\" href=\"/topics/stroke-tia/references/\">RCP, 2016</a>].<ul><li>The Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) non-inferiority study followed up 20,332 people with non-cardioembolic ischemic stroke for a mean of 2.5 years and found that recurrent stroke occurred in 9.0% of people assigned to apirin/dipyridamole compared with 8.8% assigned to clopidogrel (HR,1.01; 95% CI, 0.92–1.11). The risk of intracranial haemorrhage was not significantly different with the 2 treatments but the risk of gastrointestinal haemorrhage was increased significantly with aspirin plus extended-release dipyridamole compared with clopidogrel [<a class=\"bibliography-reference internal-reference\" href=\"/topics/stroke-tia/references/\">Kernan, 2014</a>].</li><li>Combination aspirin and clopidogrel therapy has not been found to be superior to clopidogrel monotherapy in people with recent TIA or stroke [<a class=\"bibliography-reference internal-reference\" href=\"/topics/stroke-tia/references/\">Diener et al, 2004</a>] and is associated with increased risk of adverse effects, in particular, bleeding [<a class=\"bibliography-reference internal-reference\" href=\"/topics/stroke-tia/references/\">Geraghty, 2010</a>]. </li></ul></li></ul></li><li><strong>Lipid modifying drugs</strong><ul><li>Recommendations on lipid modifying therapy are based on the clinical guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/stroke-tia/references/\">RCP, 2016</a>].</li><li>Reduction in lipid levels has been shown to be effective in the primary and secondary prevention of vascular events, including stroke [<a class=\"bibliography-reference internal-reference\" href=\"/topics/stroke-tia/references/\">RCP, 2016</a>].<ul><li>The UK Heart Protection Study (HPS) found a relative risk reduction of 17% in vascular death, 27% in major coronary events and 25% in stroke in adults at high risk of cardiovascular events with simvastatin 40 mg daily [<a class=\"bibliography-reference internal-reference\" href=\"/topics/stroke-tia/references/\">Heart Protection Study Collaborative Group, 2011</a>].</li></ul></li><li>The Stroke Prevention by Aggressive Reduction of Cholesterol Levels (SPARCL) trial (n = 4,731) found that atorvastatin 80 mg daily in people with TIA or stroke in the preceding 6 months lead to a relative risk reduction of 16% in stroke [<a class=\"bibliography-reference internal-reference\" href=\"/topics/stroke-tia/references/\">Amarenco et al, 2006</a>].</li><li>Primary and secondary prevention studies have shown that lowering low density lipoprotein (LDL) cholesterol by 1 mmol/L reduces the relative risk of major vascular events by 21%, total mortality by 9% and stroke (of any type) by 15% regardless of baseline cholesterol and gender [<a class=\"bibliography-reference internal-reference\" href=\"/topics/stroke-tia/references/\">Cholesterol Treatment Trialists&#39; (CTT) Collaboration, 2015</a>].</li><li>The NICE clinical guideline <em>Cardiovascular disease: risk assessment and reduction, including lipid modification </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/stroke-tia/references/\">NICE, 2016</a>] recommends ‘high-intensity’ statin therapy with atorvastatin 80 mg daily with a lower starting dose for people at risk of adverse effects or interactions. </li><li>Statin treatment should be avoided in people with primary intracerebral haemorrhage unless advised for other indications [<a class=\"bibliography-reference internal-reference\" href=\"/topics/stroke-tia/references/\">RCP, 2016</a>].<ul><li>In HPS, 3,280 patients had a history of stroke, TIA or carotid revascularisation. A nonsignificant 91% (95% CI –8 to 395) increase in the risk of intracerebral haemorrhage was identified with statin therapy in this group. </li><li>In SPARCL the risk of intracerebral haemorrhage was found to increase by 67% (95% CI 9–156) in those on a statin [<a class=\"bibliography-reference internal-reference\" href=\"/topics/stroke-tia/references/\">Goldstein et al, 2008</a>].</li></ul></li></ul></li><li><strong>Anti-hypertensive drugs</strong><ul><li>Recommendations on anti-hypertensive therapy are based on the clinical guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/stroke-tia/references/\">RCP, 2016</a>].</li><li>Hypertension is estimated to cause half of all ischaemic strokes and is a major risk factor for intracerebral haemorrhage — treatment of hypertension can prevent subsequent vascular events [<a class=\"bibliography-reference internal-reference\" href=\"/topics/stroke-tia/references/\">Kernan, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/stroke-tia/references/\">British Columbia Medical Association, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/stroke-tia/references/\">RCP, 2016</a>].<ul><li>A double-blinded study (The Perindopril Protection Against Recurrent Stroke Study [PROGRESS]) randomized people with history of stroke (ischaemic or haemorrhagic) or TIA (n = 6105) to a perindopril-based regime (perindopril alone or perindopril plus indapamide). The end-point of fatal or non-fatal stroke was reduced by 28% (95&CI 17–38%) in the active treatment group. Combination treatment was associated with the greatest risk reduction (RRR, 43%; 95% CI, 30%–54% [<a class=\"bibliography-reference internal-reference\" href=\"/topics/stroke-tia/references/\">Arima, 2006</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/stroke-tia/references/\">Kernan, 2014</a>].</li><li>A meta-analysis of 123 studies (n = 613,815) found that reducing systolic BP by 10 mmHg lowered the risk of stroke by 27% — calcium-channel blockers were identified as the most effective drug class [<a class=\"bibliography-reference internal-reference\" href=\"/topics/stroke-tia/references/\">Ettehad, 2015</a>].</li></ul></li><li>In most cases (excluding severe hypertension, acute intracerebral haemorrhage or before intravenous thrombolysis treatment) antihypertensive medication will be started before discharge or at 2 weeks, whichever is the soonest, or if not admitted on the first clinic visit [<a class=\"bibliography-reference internal-reference\" href=\"/topics/stroke-tia/references/\">RCP, 2016</a>].</li></ul></li><li><strong>Anticoagulation</strong><ul><li>Recommendations on anticoagulation therapy are based on the clinical guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/stroke-tia/references/\">RCP, 2016</a>].</li><li>Strong evidence supports the use of anticoagulants for long-term secondary prevention in appropriate people with paroxysmal or permanent AF [<a class=\"bibliography-reference internal-reference\" href=\"/topics/stroke-tia/references/\">British Columbia Medical Association, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/stroke-tia/references/\">RCP, 2016</a>].<ul><li>The HAS-BLED tool can be used to identify relative contraindications to anticoagulation [<a class=\"bibliography-reference internal-reference\" href=\"/topics/stroke-tia/references/\">Pisters et al, 2010</a>] and risk of bleeding may be reduced by addressing modifiable risk factors [<a class=\"bibliography-reference internal-reference\" href=\"/topics/stroke-tia/references/\">RCP, 2016</a>].</li><li>The use of aspirin is not recommended unless there are additional indications unrelated to AF – if bleeding risk is thought to be too high to use an anticoagulant aspirin is <em>not</em> a safer alternative (particularly among older patients) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/stroke-tia/references/\">Mant et al, 2007</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/stroke-tia/references/\">NICE, 2014a</a>].</li><li>A left atrial appendage occlusion device may be suitable for certain people who cannot be treated in the long term with anticoagulation but can tolerate short-term anticoagulation following the procedure [<a class=\"bibliography-reference internal-reference\" href=\"/topics/stroke-tia/references/\">RCP, 2016</a>].</li></ul></li><li>Selection of anticoagulant agent is based on specialist clinical judgement and takes into account factors such as renal and hepatic function, drug interactions, patient preference, cost, and tolerability. Oral anticoagulation may not be appropriate in some people [<a class=\"bibliography-reference internal-reference\" href=\"/topics/stroke-tia/references/\">Hankey, 2014</a>].</li><li>Timing of initiation of anticoagulation in people with AF associated stroke is based on clinical judgment taking into account risk of haemorrhagic transformation and recurrent stroke [<a class=\"bibliography-reference internal-reference\" href=\"/topics/stroke-tia/references/\">British Columbia Medical Association, 2015</a>].<ul><li>The Royal College of Physicians recommend a delay in initiation of anticoagulation of 2 weeks after acute cardioembolic stroke due to the risk of haemorrhagic transformation but advise that specialists may initiate therapy earlier, depending on clinical judgement, for minor, non-disabling strokes with lower risk of haemorrhagic transformation [<a class=\"bibliography-reference internal-reference\" href=\"/topics/stroke-tia/references/\">RCP, 2016</a>].</li><li>People with TIA and AF can usually begin oral anticoagulation immediately as risk of intracranial haemorrhage is likely to be low [<a class=\"bibliography-reference internal-reference\" href=\"/topics/stroke-tia/references/\">Hankey, 2014</a>].</li></ul></li></ul></li></ul><h5 style=\"margin-left: 18.0pt;\">Optimize management of other comorbidities</h5><ul><li>Comorbidities which are risk factors for cardiovascular disease should be managed optimally to reduce risk [<a class=\"bibliography-reference internal-reference\" href=\"/topics/stroke-tia/references/\">Jauch, 2013</a>].<ul><li><strong>Diabetes mellitus (DM)</strong> — DM is a clear risk factor for first stroke but evidence is less conclusive for recurrent stroke [<a class=\"bibliography-reference internal-reference\" href=\"/topics/stroke-tia/references/\">British Columbia Medical Association, 2015</a>]. The American Heart Association/American Stroke Association recommend that following TIA or ischemic stroke, all people are screened for DM and treated appropriately if DM or pre-DM is identified [<a class=\"bibliography-reference internal-reference\" href=\"/topics/stroke-tia/references/\">Kernan, 2014</a>].</li><li><strong>Obstructive sleep apnoea (OSA)</strong> — Cardiovascular risk factors (such as hypertension, hyperlipidaemia, diabetes, smoking, AF and obesity) are more common in OSA but it has also been found to be an independent risk factor for stroke [<a class=\"bibliography-reference internal-reference\" href=\"/topics/stroke-tia/references/\">Loke et al, 2012</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/stroke-tia/references/\">Kernan, 2014</a>].</li><li><strong>Oral contraception/Hormone replacement therapy (HRT) </strong>— oestrogen (either used by younger women as the combined oral contraceptive or by post-menopausal women as HRT) increases the risk of cardiovascular events including ischaemic stroke [<a class=\"bibliography-reference internal-reference\" href=\"/topics/stroke-tia/references/\">RCP, 2016</a>].</li><li><strong>Influenza</strong> — The recommendations on who should be offered annual influenza immunization are based on the chapter on influenza in the Public Health England <em>Green Book</em><em> </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/stroke-tia/references/\">PHE, 2015</a>].</li></ul></li></ul><!-- end field 6dc9f4a3-b600-4804-8221-c307432752a1 --><!-- end item 218c62c7-0f6e-4323-8ef5-594f0fe24e57 -->","subChapters":[]}]}]}}},"staticQueryHashes":["3666801979"]}